藥明康德：出售藥明合聯7.17%股份，累計實現投資收益20.16億元

市場資訊

01-13

　　藥明康德公告，公司通過間接控股子公司累計出售藥明合聯8600萬股股票，約佔藥明合聯當前總股本的7.17%，累計成交金額約24.26億港元，佔公司最近一期經審計歸屬母公司股東淨資產的4.07%。經初步覈算，過去十二個月內公司出售藥明合聯股票累計實現的投資收益爲人民幣20.16億元，佔公司最近一期經審計歸屬母公司股東淨利潤的比例超過10%，其中影響公司2024年度當期淨利潤約爲人民幣7.2億元，影響公司2025年度當期淨利潤約爲人民幣12.97億元。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：張倩

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503237875"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503237875\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503237875?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-13 17:10","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2503237875","market":"other","top_or_hot":-1,"title":"藥明康德：出售藥明合聯7.17%股份，累計實現投資收益20.16億元","media":"市場資訊","content":"<html><body><div>\n<p>　　<span><a href=\"https://laohu8.com/S/603259\">藥明康德</a></span><span></span>公告，公司通過間接控股子公司累計出售<span><a href=\"https://laohu8.com/S/02268\">藥明合聯</a></span><span></span>8600萬股股票，約佔藥明合聯當前總股本的7.17%，累計成交金額約24.26億港元，佔公司最近一期經審計歸屬母公司股東淨資產的4.07%。經初步覈算，過去十二個月內公司出售藥明合聯股票累計實現的投資收益爲人民幣20.16億元，佔公司最近一期經審計歸屬母公司股東淨利潤的比例超過10%，其中影響公司2024年度當期淨利潤約爲人民幣7.2億元，影響公司2025年度當期淨利潤約爲人民幣12.97億元。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張倩 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>藥明康德：出售藥明合聯7.17%股份，累計實現投資收益20.16億元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n藥明康德：出售藥明合聯7.17%股份，累計實現投資收益20.16億元\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">市場資訊</strong><span class=\"h-time small\">2025-01-13 17:10</span>\n</p>\n</header>\n<article>\n<div>\n<p>　　<span><a href=\"https://laohu8.com/S/603259\">藥明康德</a></span><span></span>公告，公司通過間接控股子公司累計出售<span><a href=\"https://laohu8.com/S/02268\">藥明合聯</a></span><span></span>8600萬股股票，約佔藥明合聯當前總股本的7.17%，累計成交金額約24.26億港元，佔公司最近一期經審計歸屬母公司股東淨資產的4.07%。經初步覈算，過去十二個月內公司出售藥明合聯股票累計實現的投資收益爲人民幣20.16億元，佔公司最近一期經審計歸屬母公司股東淨利潤的比例超過10%，其中影響公司2024年度當期淨利潤約爲人民幣7.2億元，影響公司2025年度當期淨利潤約爲人民幣12.97億元。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張倩 </p>\n</div>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-13/doc-ineevkux9565561.shtml\">市場資訊</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2045819591.USD","symbol_name":"Natixis WCM Global Emerging Markets Equity R/A USD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-01-13/doc-ineevkux9565561.shtml","article_id":"2503237875","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503237875","pubTimestamp":1736759400,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"藥明康德公告，公司通過間接控股子公司累計出售藥明合聯8600萬股股票，約佔藥明合聯當前總股本的7.17%，累計成交金額約24.26億港元，佔公司最近一期經審計歸屬母公司股東淨資產的4.07%。經初步核算，過去十二個月內公司出售藥明合聯股票累計實現的投資收益為人民幣20.16億元，佔公司最近一期經審計歸屬母公司股東淨利潤的比例超過10%，其中影響公司2024年度當期淨利潤約為人民幣7.2億元，影響公司2025年度當期淨利潤約為人民幣12.97億元。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：張倩","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1997245177.USD":"安联神洲A股基金","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","02268":"药明合联","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","02359":"药明康德","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1583":"高瓴概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK0216":"研究试验"},"translate_title":"WuXi AppTec: Sold 7.17% shares of WuXi United, achieving a cumulative investment income of 2.016 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1,"02268":1},"content_text":"藥明康德公告，公司通過間接控股子公司累計出售藥明合聯8600萬股股票，約佔藥明合聯當前總股本的7.17%，累計成交金額約24.26億港元，佔公司最近一期經審計歸屬母公司股東淨資產的4.07%。經初步核算，過去十二個月內公司出售藥明合聯股票累計實現的投資收益為人民幣20.16億元，佔公司最近一期經審計歸屬母公司股東淨利潤的比例超過10%，其中影響公司2024年度當期淨利潤約為人民幣7.2億元，影響公司2025年度當期淨利潤約為人民幣12.97億元。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：張倩","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0}}}